Zynex, Inc.

Zynex, Inc. is a medical device company that specializes in non-invasive pain management technologies. The company develops and manufactures electrotherapy devices to provide pain relief and rehabilitation support for patients. Their innovative approach focuses on enhancing the quality of patient care through advanced medical technologies.

CCI Score

-65.24

0.27% May 31

Latest Event

Securities Class Action Filed Against Zynex for Revenue Inflation

A class action complaint filed on March 20, 2025, alleges that Zynex, Inc. engaged in unethical business practices by shipping products, including electrodes, in excess of demand, resulting in inflated revenue figures and misleading investors about the company’s financial health.

Take Action

So what can you do? It's time to make tough choices. Where will you cast your vote?

Shop Alternatives SEE ALL: Nyxoah

PEPFAR

ICU Medical
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

ARCHITECT

Zynex, Inc. is currently rated as an Architect.

-60 to -100 CCI Score

Companies in this category are instrumental in designing and executing authoritarian rule. They actively create and implement frameworks that sustain oppressive policies, wielding considerable influence in shaping autocratic systems.

Latest Events

MAR

20

2025

Securities Class Action Filed Against Zynex for Revenue Inflation
-58.81

A class action complaint filed on March 20, 2025, alleges that Zynex, Inc. engaged in unethical business practices by shipping products, including electrodes, in excess of demand, resulting in inflated revenue figures and misleading investors about the company’s financial health.
-60

Business Practices and Ethical Responsibility

April 30

The complaint asserts that Zynex deliberately inflated revenue by shipping more products than needed, a practice that undermines business transparency and ethical responsibility. Such misleading disclosures can harm investor trust and reflect poorly on corporate governance.

Securities Class Action Clearinghouse: Case Page
MAR

11

2025

Class Action Allegations Over Revenue Inflation
-78.23

A class action was initiated alleging that Zynex, Inc. inflated its revenue by shipping products in excess and filing false claims, which led to a significant stock price drop and scrutiny from insurers such as Tricare.
-80

Business Practices and Ethical Responsibility

April 30

The allegations suggest that Zynex engaged in unethical business practices by inflating revenue and filing false claims, actions that undermine corporate transparency and accountability. Such behavior falls under 'Business Practices and Ethical Responsibility' and represents a negative impact on stakeholder trust.

Zynex, Inc. Class Action
MAR

11

2025

Zynex Faces Securities Class Action Over Alleged Fraudulent Sales Practices
-58.67

A securities class action lawsuit alleges that Zynex, Inc. engaged in an oversupply scheme by shipping product in excess of customer needs to inflate revenues and mislead investors. The complaint also contends that the company’s false and misleading statements about its relationship with the military health program, Tricare, contributed to adverse consequences such as potential removal from insurer networks and regulatory penalties. The allegations emerged following a dismal Q4 and FY 2024 financial report, sparking investor concern and legal action.
-60

Business Practices and Ethical Responsibility

April 30

The lawsuit alleges that Zynex engaged in deceptive revenue recognition and oversupply practices to inflate sales figures, representing a significant breach in ethical business practices. Such corporate malfeasance undermines investor trust and transparency, aligning with concerns associated with unethical business conduct.

Zynex, Inc. (ZYXI) Securities Class Action